Prevention of cardiovascular disease

Trends in Cardiovascular Medicine

Volumn 25, Issue 5, 2015, Pages 436-442

  Cohn, Jay N ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; COST BENEFIT ANALYSIS; HEART PROTECTION; HUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING; STRATEGIC PLANNING; CARDIOVASCULAR DISEASES; EARLY DIAGNOSIS; MASS SCREENING; PHENOTYPE; POLYPHARMACOLOGY; PROCEDURES;

CARDIOVASCULAR DISEASES; EARLY DIAGNOSIS; HUMANS; MASS SCREENING; PHENOTYPE; POLYPHARMACOLOGY;

EID: 84930766407     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2014.12.005     Document Type: Review

References (30)

1. Staessen J.A., Wang J.G., Thijs L. Cardiovascular protection and blood pressure reduction: a meta analysis. Lancet 2001, 358:1305-1315.
2. Turnbull F. Effects of different blood-pressure lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003, 362:1527-1535. Blood Pressure Lowering Treatment Trialists' Collaboration.
3. The Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145-153.
4. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicenter trial (the EUROPA study). Lancet 2003, 362:782-788.
5. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
6. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:581-590. Cholesterol Treatment Trialists' (CTT) Collaborators.
7. Peters S.A.E., den Ruijter H.M., Bots M.L., Moons K.G.M. Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review. Heart 2012, 98:177-184.
8. Cohn J.N., Duprez D.A. Time to foster a rational approach to preventing cardiovascular morbid events. J Am Coll Cardiol 2008, 52:327-329.
9. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
10. Lewington S., Whitlock G., Clarke R., Sherliker P., Emberson J., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007, 370:1829-1839. Prospective Studies Collaboration.
11. James P.A., Oparil S., Carter B.L., Cushman W.C., Dennison-Himmelfarb C., Handler J., et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). J Am Med Assoc 2014, 311:507-520.
12. Goff D.C., Lloyd-Jones D.M., Bennett G., Coady S., D'Agostino R.B., Gibbons R., et al. ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014, 129:S49-S73.
13. D'Agostino R.B., Vasan R.S., Pencina M.J., Wolf P.A., Cobain M., Massaro J.M., et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008, 117:743-753.
14. Kotseva K., Wood D., De Backer G., De Bacquer D., Pyörälä K., Keil U., et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009, 373:929-940.
15. Wald N.J., Law M.R. A strategy to reduce cardiovascular disease by more than 80%. Br Med J 2003, 326:1419-1423.
16. Lonn E., Bosch J., Teo K.K., Pais P., Xavier D., Yusuf S. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges and future directions. Circulation 2010, 122:2078-2088.
17. The Indian Polycap Study (TIPS) Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomized trial. Lancet 2009, 373:1341-1351.
18. Castellano J.M., Sanz G., Ortiz A.F., Garrido E., Bansilal S., Fuster V. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality. J Am Coll Cardiol 2014, 64:613-621.
19. Gilani M., Kaiser D.R., Bratteli C.W., Alinder C., Rajala S., Bank A.J., et al. Role of nitric oxide deficiency and its detection as a risk factor in pre-hypertension. J Am Soc Hypertens 2007, 1:45-55.
20. Den Ruijter H.M., Peters S.A.E., Anderson T.J., Britton A.R., Dekker J.M., Eijkemans M.J., et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. J Am Med Assoc 2012, 308:796-803.
21. Weir M.R. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol 2007, 2:581-590.
22. Celermajer D.S., Sorensen K.E., Gooch V.M., Spiegelhalter D.J., Miller O.I., Sullivan I.D., et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992, 340:1111-1115.
23. Cohn J.N., Hoke L., Whitwam W., Sommers P.A., Taylor A.L., Duprez D., et al. Screening for early detection of cardiovascular disease in asymptomatic individuals. Am Heart J 2003, 146:679-685.
24. Duprez D.A., Cohn J.N. Identifying early cardiovascular disease to target candidates for treatment. J Clin Hypertens (Greenwich) 2008, 10:226-231.
25. Duprez D.A., Florea N., Zhong W., Grandits G.A., Hawthorne C.K., Hoke L., et al. Vascular and cardiac functional and structural screening to identify risk of future morbid events: preliminary observations. J Am Soc Hypertens 2011, 5:401-409.
26. Duprez D.A., Florea N.D., Jones K., Cohn J.N. Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study. J Am Coll Cardiol 2007, 50:835-839.
27. Saul S.M., Duprez D.A., Zhong W., Grandits G.A., Cohn J.N. Effect of carvedilol, lisinopril and their combination on vascular and cardiac health in patients with borderline blood pressure: the DETECT study. J Hum Hypertens 2013, 27:362-367.
28. Laupacis A., Sackett D.L., Roberts R.S. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988, 318:1728-1733.
29. 27th Bethesda Conference Matching the intensity of risk factor management with the hazard for coronary disease events. September 14-15, 1995. J Am Coll Cardiol 1996, 27:957-1047.
30. Ridker P.M., Danielson E., Fonseca F.A.H., Genest J., Gotto A.M., Kastelein J.J.P., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.